Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 study of selpercatinib (Retevmo) in RET-mutant medullary thyroid carcinoma has results posted (June 13, 2024); the trial is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Medullary Thyroid Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-13